Full-Time

Director – New Product Planning

Posted on 9/19/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

70/30 work model; 70% in-office presence required.

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Requirements
  • 8+ years of experience working for a clinical- or commercial-stage pharmaceutical/biotech company in strategy or new product planning
  • MBA or PhD preferred, with an understanding of drug development and value creation in the biopharmaceutical industry, and commitment to learn about the science behind our platform technology
Responsibilities
  • Act as a strategic thought partner for early clinical-stage program teams, providing insights and guidance to ensure informed decision-making at the program level
  • Develop a deep understanding of market dynamics, competitive landscapes, patient needs, and target biology to lead the generation and analysis of required evidence to support product value and differentiation
  • Drive primary and secondary market research and engage with external experts, KOLs, and advisory boards to distill market trends, assess unmet needs, and gather insights on customer behavior
  • Oversee the creation, refinement and evolution of Target Product Profiles (TPPs), ensuring alignment with program strategic objectives and market needs
  • Lead generation of program and market assumptions for market sizing and revenue forecasting
  • Craft compelling value propositions that resonate with stakeholders and support market access strategies
  • Collaborate closely with Research, Development, Commercial, Finance, CMC and additional functions maximize the value of the program for patients and our platform

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treatment options for patients. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the discovery, development, and manufacturing processes of medicines. The company's goal is to leverage the unique properties of mRNA to improve patient outcomes and create a new category of effective treatments.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Opening a new vaccine facility in Victoria enhances manufacturing capabilities.
  • Strategic investment in China boosts Moderna's presence in the Asian market.
  • Collaboration with Carisma Therapeutics could lead to breakthroughs in autoimmune treatments.

What critics are saying

  • Potential removal from Nasdaq 100 could impact investor perception.
  • Reticence in Hong Kong for Covid-19 jab indicates market penetration challenges.
  • Expansion into China may expose Moderna to geopolitical and regulatory risks.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for innovative medical treatments.
  • The company has a strong focus on developing vaccines for infectious diseases.
  • Moderna's mRNA platform enables rapid development of therapeutics and vaccines.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE